Actinogen Medical Boosts Leadership with New CCO
Company Announcements

Actinogen Medical Boosts Leadership with New CCO

Actinogen Medical Limited (AU:ACW) has released an update.

Actinogen Medical Limited has appointed Andrew Udell as Chief Commercial Officer to bolster its leadership team as it advances clinical trials for its promising Alzheimer’s and depression treatment, Xanamem. Udell brings extensive experience from his successful tenure at Calliditas Therapeutics, where he led a US product launch. Actinogen hopes his expertise will aid in the commercial readiness of their novel therapy targeting central nervous system disorders.

For further insights into AU:ACW stock, check out TipRanks’ Stock Analysis page.

Related Articles
TipRanks Australian Auto-Generated NewsdeskActinogen Medical Highlights Alzheimer’s Research Progress
TipRanks Australian Auto-Generated NewsdeskActinogen Medical Advances Alzheimer’s Trials and Boosts Capital
TipRanks Australian Auto-Generated NewsdeskActinogen Medical Plans New Share Issue Amid Xanamem Progress
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App